Schedule 13G ownership disclosure
ArriVent Biopharma Inc
Common Stock · CUSIP: 04272N102
Event date: 2025-09-30
- Filing-level shares
- 2,029,531
- Percent of class
- 5%
- The Vanguard Group
Shares: 2,029,531 · Class: 5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-25-000025
- Form type
- SCHEDULE 13G
- Filer
- ArriVent BioPharma, Inc.
- CIK
- CIK 1868279
- Filed
- Oct 30, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership